No Data
Zhendong Pharmaceutical: 2024 Annual Results Forecast
Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Is In A Good Position To Deliver On Growth Plans
Shanxi Zhendong Pharmaceutical (300158.SZ): has cumulatively repurchased 0.3 million shares.
Shanxi Zhendong Pharmaceutical (300158.SZ) announced that, as of November 30, 2024, the company has cumulatively repurchased 0.3 million shares of the company through the share repurchase special securities account in a centralized auction trading manner, accounting for 0.03% of the company's current total share capital. The highest fill price for repurchase was RMB 5.03 per share, while the lowest fill price was RMB 5.01 per share, with a total transaction amount of RMB 1,506,000 (excluding transaction fees).
Shareholders in Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Have Lost 8.5%, as Stock Drops 7.1% This Past Week
Revenues Working Against Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Share Price Following 26% Dive